Novartis receives FDA approval for Rhapsido® , the only oral, targeted BTKi treatment for chronic spontaneous urticaria
Precious Metals & Critical Minerals Virtual Investor Conference Presentations Now Available for On-Demand Viewing
CoTec Holdings Corp. Announces Final Closing of Private Placement of Unsecured Convertible Debentures, Total Raise of $20 Million
